Real-World Analysis Explores GLP-1 Use and Overall Survival

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, investigators presented findings from a large real-world analysis evaluating the association between glucagon-like peptide-1 (GLP-1) receptor agonist use and overall survival among patients treated in community oncology practices. In an interview with Targeted OncologyTM, Jessica Paulus, ScD, of Ontada, discusses the rationale for the study and key findings.

Paulus explains that although GLP-1 receptor agonists have become widely used for diabetes and weight management, growing preclinical and epidemiologic evidence has suggested these agents may also have anticancer effects. However, previous studies have generally been limited in scope and have not evaluated outcomes across a broad range of tumor types in a large community oncology population.

To address this gap, investigators analyzed real-world data from patients receiving care in community oncology settings. The study found that GLP-1 receptor agonist use was associated with a 34% reduction in the risk of death compared with nonuse. According to Paulus, this survival association remained consistent across multiple analytic approaches designed to reduce the effects of confounding and other biases commonly encountered in observational research.

Paulus emphasizes that the analysis demonstrates an association rather than causation. She highlights the biological plausibility supporting further investigation and that prospective clinical studies will be needed to determine whether GLP-1 receptor agonists directly contribute to improved cancer outcomes.